Advertisement
SAN ANTONIO, Dec. 11, 2019 /PRNewswire-PRWeb/ -- Clinical Trials of Texas, Inc. (CTT) is proud to announce the addition of Thomas R. Weiss, MD to its research site. Dr. Weiss will be responsible for oversight of Central Nervous System (CNS) research studies as a Principal Investigator (PI).
Dr. Weiss, who has a private psychiatry practice in San Antonio, has participated in more than 400 research studies over a span of 20 years. Some of the CNS treatments he has overseen in trials include dozens of medications that have been brought to market including Vraylar®, Namenda®, Trintellix®, Cymbalta®, Lexapro® and Lunesta®. He is also frequently sought after to participate in the speakers' bureaus for pharmaceutical companies because of his expertise in CNS clinical research.
A former military doctor, Dr. Weiss spent 14 years in active duty in the Air Force and 9 years in the Navy Reserve. He is a Diplomate of the American Board of Psychiatry and Neurology with Certificates of Added Qualifications in Addiction, Geriatric and Psychosomatic Medicine.
"I feel fortunate to be joining forces with CTT at such an exciting time for CNS research," said Dr. Weiss. "There is so much new science making breakthrough therapies in areas of glutamatergic agents, MNDA agonist and antagonists, inflammatory modalities and devices."
CTT is a woman-owned business founded in 2001 by Kay Scroggins, RN. The research site has grown to be one of the largest and most prestigious multi-therapeutic clinical trial facilities in the U.S. CTT conducts studies in phases I-IV across more than 50 indications including CNS, diabetes, liver disease, women's and men's health, vaccine, healthy participants, dermatology, rheumatology, memory loss and devices.Connect with CTT via its website, Facebook, LinkedIn or Twitter.
SOURCE Clinical Trials of Texas
Advertisement
Dr. Weiss, who has a private psychiatry practice in San Antonio, has participated in more than 400 research studies over a span of 20 years. Some of the CNS treatments he has overseen in trials include dozens of medications that have been brought to market including Vraylar®, Namenda®, Trintellix®, Cymbalta®, Lexapro® and Lunesta®. He is also frequently sought after to participate in the speakers' bureaus for pharmaceutical companies because of his expertise in CNS clinical research.
A former military doctor, Dr. Weiss spent 14 years in active duty in the Air Force and 9 years in the Navy Reserve. He is a Diplomate of the American Board of Psychiatry and Neurology with Certificates of Added Qualifications in Addiction, Geriatric and Psychosomatic Medicine.
"I feel fortunate to be joining forces with CTT at such an exciting time for CNS research," said Dr. Weiss. "There is so much new science making breakthrough therapies in areas of glutamatergic agents, MNDA agonist and antagonists, inflammatory modalities and devices."
CTT is a woman-owned business founded in 2001 by Kay Scroggins, RN. The research site has grown to be one of the largest and most prestigious multi-therapeutic clinical trial facilities in the U.S. CTT conducts studies in phases I-IV across more than 50 indications including CNS, diabetes, liver disease, women's and men's health, vaccine, healthy participants, dermatology, rheumatology, memory loss and devices.Connect with CTT via its website, Facebook, LinkedIn or Twitter.
SOURCE Clinical Trials of Texas
